HC Wainwright Issues Negative Outlook for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at HC Wainwright cut their Q1 2026 EPS estimates for Agenus in a report issued on Monday, March 16th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn $1.45 per share for the quarter, down from their previous estimate of $1.49. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at $0.41 EPS.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.83. The business had revenue of $34.20 million during the quarter, compared to analysts’ expectations of $28.10 million. Agenus had a negative return on equity of 7.44% and a negative net margin of 2.67%.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Agenus has an average rating of “Hold” and an average price target of $14.50.

Agenus Trading Up 21.3%

Shares of AGEN opened at $3.99 on Wednesday. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The company has a market cap of $135.70 million, a PE ratio of -8.67 and a beta of 1.57. The stock has a 50-day moving average price of $3.27 and a 200-day moving average price of $3.77.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently added to or reduced their stakes in the company. LPL Financial LLC boosted its holdings in shares of Agenus by 20.3% in the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 3,943 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Agenus during the 4th quarter valued at about $31,000. Catalyst Funds Management Pty Ltd bought a new stake in Agenus in the 2nd quarter worth approximately $50,000. Jump Financial LLC purchased a new stake in Agenus in the second quarter worth approximately $55,000. Finally, Traynor Capital Management Inc. bought a new position in Agenus during the third quarter valued at approximately $50,000. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.